Juha Rantala

Dr. Juha Rantala


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2014 in Science
Verified
Journal Article
Closed access
PDF file
LCLorenzo Costantino
Lorenzo Costantino
SSSotirios K. Sotiriou
Sotirios K. Sotiriou
JRJuha Rantala
Juha Rantala
SMSimon Magin
Simon Magin
EMEmil Mladenov
Emil Mladenov
THThanos Halazonetis
Thanos Halazonetis
DNA Damage Repair: In human cancers, oncogene activation interferes with DNA replication, leading to DNA replication stress and DNA double-strand breaks (DSBs). Costantino et al. (p. 88 , published online 5 December) identified two subunits of DNA polymerase delta, POL3 and POL4, as critical for survival of DNA replication stress in human cells. Both subunits were required for break-induced replication (BIR), which is required to repair a specific type of DSB, with both subunits possibly required for processive DNA synthesis in BIR. Tandem head-to-tail duplications and fold-back inversions were seen in replication-stressed cells, similar to those seen in human breast and ovarian cancers, suggesting that BIR is important for repairing damaged forks in cancer cells.

31 August 2010 in Cancer Research
Verified
Journal Article
Closed access
PDF file
SGSantosh Gupta
Santosh Gupta
KIKristiina Iljin
Kristiina Iljin
HSHenri Sara
Henri Sara
JMJohn Patrick Mpindi
John Patrick Mpindi
TMTuomas Mirtti
Tuomas Mirtti
OKOlli Kallioniemi
Olli Kallioniemi
TMPRSS2-ERG and other gene fusions involving ETS factors and genes with strong promoter elements are common in prostate cancer. Although ERG activation has been linked to invasive properties of prostate cancers, the precise mechanisms and pathways of ERG-mediated oncogenesis remain poorly understood. Here, we show that ERG knockdown in VCaP prostate cancer cells causes an activation of cell adhesion, resulting in strongly induced active β1-integrin and E-cadherin expression as well as changes in WNT signaling. These observations were corroborated by data from ERG-overexpressing nontransformed prostate epithelial cells as well as gene expression data from clinical prostate cancer samples, which both indicated a link between ERG and epithelial-to-mesenchymal transition (EMT). Upregulation of several WNT pathway members was seen in ERG-positive prostate cancers, with frizzled-4 (FZD4) showing the strongest overexpression as verified by both reverse transcription-PCR and immunostaining. Both ERG knockin and knockdown modulated the levels of FZD4 expression. FZD4 silencing could mimic the ERG knockdown phenotype by inducing active β1-integrin and E-cadherin expression, whereas FZD4 overexpression reversed the phenotypic effects seen with ERG knockdown. Taken together, our results provide mechanistic insights to ERG oncogenesis in prostate cancer, involving activation of WNT signaling through FZD4, leading to cancer-promoting phenotypic effects, including EMT and loss of cell adhesion. Cancer Res; 70(17); 6735–45. ©2010 AACR.

25 September 2011 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
JRJuha Rantala
Juha Rantala
JPJeroen Pouwels
Jeroen Pouwels
TPTeijo Pellinen
Teijo Pellinen
SVStefan Veltel
Stefan Veltel
PLPetra Laasola
Petra Laasola
JIJohanna Ivaska
Johanna Ivaska

1 September 2008 in Developmental Cell
Verified
Journal Article
Closed access
TPTeijo Pellinen
Teijo Pellinen
STSaara Tuomi
Saara Tuomi
AAAntti Arjonen
Antti Arjonen
MWMaija Wolf
Maija Wolf
HEHenrik Edgren
Henrik Edgren
JIJohanna Ivaska
Johanna Ivaska

19 September 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
TRTyler Risom
Tyler Risom
ELEllen M. Langer
Ellen M. Langer
MCMargaret P. Chapman
Margaret P. Chapman
JRJuha Rantala
Juha Rantala
AFAndrew J. Fields
Andrew J. Fields
RSRosalie C. Sears
Rosalie C. Sears
Intratumoral heterogeneity in cancers arises from genomic instability and epigenomic plasticity and is associated with resistance to cytotoxic and targeted therapies. We show here that cell-state heterogeneity, defined by differentiation-state marker expression, is high in triple-negative and basal-like breast cancer subtypes, and that drug tolerant persister (DTP) cell populations with altered marker expression emerge during treatment with a wide range of pathway-targeted therapeutic compounds. We show that MEK and PI3K/mTOR inhibitor-driven DTP states arise through distinct cell-state transitions rather than by Darwinian selection of preexisting subpopulations, and that these transitions involve dynamic remodeling of open chromatin architecture. Increased activity of many chromatin modifier enzymes, including BRD4, is observed in DTP cells. Co-treatment with the PI3K/mTOR inhibitor BEZ235 and the BET inhibitor JQ1 prevents changes to the open chromatin architecture, inhibits the acquisition of a DTP state, and results in robust cell death in vitro and xenograft regression in vivo.

28 November 2011 in Oncogene
Verified
Journal Article
Closed access
MBM Björkman
M Björkman
PÖP Östling
P Östling
VHV Härmä
V Härmä
JVJ Virtanen
J Virtanen
JMJ-P Mpindi
J-P Mpindi
Matthias NeesMatthias Nees
Matthias Nees